Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MediciNova has completed enrollment of 297 patients with relapsing multiple sclerosis in a phase II clinical trial of its orally administered drug candidate, MN-166.
Subscribe to our email newsletter
The company is now developing the drug in an MS indication, although for the past 16 years the drug has been marketed in Japan and South Korea as Ketas for the treatment of asthma and cerebrovascular disorders.
MediciNova acquired the global rights to MN-166 excluding Japan, China, Taiwan and South Korea, from Kyorin Pharmaceutical Co.
Recently, MN-166 was found to have beneficial effects in several pilot clinical trials conducted in MS patients in Japan.
“MN-166 may be an effective new approach to treating MS with the added advantage of oral dosing. Rapid completion of enrollment in this relatively large trial demonstrates our commitment to advancing our clinical programs efficiently though the phase II proof-of-concept stage and beyond,” said Dr Yuichi Iwaki, executive chairman of MediciNova.